SEARCH

SEARCH BY CITATION

References

  • 1
  • 2
  • 3
    Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 4
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
  • 5
    Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, et al. IL28B Polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy [Abstract 12]. J Hepatol 2011; 54(Suppl 1): S6.
  • 6
    Poordad F, McCone J, Bacon BR, et al. Boceprevir combined with peginterferon alfa-2b/ribavirin for treatment-naive patients with HCV genotype 1: SPRINT-2 final results [Abstract LB4]. HEPATOLOGY 2010; 52(Suppl).
  • 7
    Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial [Abstract 1369]. J Hepatol 2011; 54(Suppl 1):S542–S543.
  • 8
    Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials [Abstract 8]. J Hepatol 2011;54(Suppl 1):S4.
  • 9
    Aerssens J, Fanning G, Scholliers A, Lenz O, Peeters M, De Smedt G, et al. Impact of IL28B genotype and pretreatment serum IP-10 in treatment-naive genotype-1 HCV patients treated with TMC435 in combination with peginterferonα-2A and ribavirin in PILLAR study [Abstract 11]. J Hepatol 2011;54(Suppl 1):S5-S6.
  • 10
    Zeuzem S, Foster GR, Fried MW, et al. The ASPIRE trial: TMC435 in treatment-experienced patients with genotype-1 HCV infection who have failed previous pegIFN/RBV treatment [Abstract 1376]. J Hepatol 2011; 54(Suppl 1):S546.
  • 11
    Lok AS, Gardiner DF, Lawitz E, et al. Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders [Abstract LB-8]. HEPATOLOGY 2011; 54(Suppl): 877A.
  • 12
    Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, et al. First report of SVR12 for a NS5A replication complex inhibitor BMS-790052 in combination with Peg-IFNα-2A and RBV: Phase 2A trial in treatment-naive HCV-genotype-1 subjects [Abstract 1373]. J Hepatol 2011; 54(Suppl 1):S544-S545.
  • 13
    Pockros P, Jensen D, Tsai N, et al. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial [Abstract 1359]. J Hepatol 2011; 54(Suppl 1): S538.
  • 14
    Nelson DR, Lalezari J, Lawitz E, Hassanein T, Kowdley K, Poordad F, et al. Once daily PSI-7977 plus peg-IFN/RBV in HCV GT1: 98% rapid virologic response, completely early virologic responet: The PROTON study [Abstract 1372]. J Hepatol 2011;54(Suppl 1):S544.
  • 15
    Muir AJ, Lawitz E, Rodriguez-Torres M, et al. IL28B polymorphism and kinetics of antiviral activity for ANA598 in combination with pegylated interferon alpha-2a plus ribavirin in treatment-naive genotype-1 chronic HCV patients [Abstract 1852]. HEPATOLOGY 2010; 52(Suppl);1200A.
  • 16
    Flisiak R, Pawlotsky JM, Crabbé R, et al. Once daily alisporivir (DEB025) plus pegIFNalfa2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients [Abstract 4]. J Hepatol 2011; 54(Suppl 1): S2.
  • 17
    Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.
  • 18
    Chu T, Kulkarni R, Gane EJ, et al. The effect of host IL28B genotype on early viral kinetics during interferon-free treatment in patients with chronic hepatitis C (CHC) [Abstract 1323]. J Hepatol 2011; 54 ( S1): S521.
  • 19
    Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005; 102: 2986-2991.
  • 20
    Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102: 2992-2997.
  • 21
    Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 2006; 103: 6001-6006.
  • 22
    Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172.
  • 23
    Zeuzem S, Soriano V, Asselah T, et al. Virololgic Rresponse to an interferon-free regimen of BI201335 and BI207127, with and without rivavirin, in treatement-naive patients with chronic genotype-1 HCV infection: Week 12 interim results of the SOUND-C2 STUDY [Abstract LB-15]. HEPATOLOGY 2011; 54(Suppl): 1436A.
  • 24
    Chayama K, Takahashi S, Kawakami Y, Ikeda K, et al. Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1B-infected null responders [Abstract LB-4]. HEPATOLOGY 2011; 54(Suppl): 1428A.
  • 25
    Muir AJ, Lawitz E, Ghalib RH, et al. Pegylated interferon lambda (PEG-IFN-λ) phase 2 dose-ranging, active controlled study in combination with ribavirin (RBV) for treatment naive HCV patients (genotype 1,2,3 or 4): safety, viral response and impact of IL28B host genotype through week 12 [Abstract 821]. HEPATOLOGY 2010; 52(Suppl): 715A.
  • 26
    Zeuzem S, Arora S, Bacon BR, et al. Pegylated interferon-lambda (PegIFN-λ) shows superior viral response with improved safety and tolerability versus PegIFN-2α in HCV patients (G1/2/3/4): EMERGE phase IIb through week 12 [Abstract 1360]. J Hepatol 2011; 54(Suppl 1): S538-S539.
  • 27
    Muir AJ, Lawitz E, Rodriguez-Torres M, et al. IL28B polymorphism and kinetics of antiviral activity for ANA598 in combination with pegylated interferon α 2A plus ribavirin in treatment-naive genotype-1 chronic HCV patients [Abstract 1852]. HEPATOLOGY 2010; 52(Suppl):1200A.
  • 28
    Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15: 31-33.
  • 29
    Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
  • 30
    Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. HEPATOLOGY 2010; 52: 1888-1896.
  • 31
    Schiff ER, Everson GT, Tsai N, et al. HCV-specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI-5005, a yeast-based immunotherapy targeting NS3 and core: a randomized, double-blind, placebo-controlled phase 1b study. HEPATOLOGY 2007; 46(Suppl): A1304.
  • 32
    Pockros P, Jacobson IM, Boyer TD, et al. GI-5005 Therapeutic vaccine plus Peg-IFN/ribavirin improves sustained virologic response versus Peg-IFN/ribavirin in prior non-responders with genotype 1 chronic HCV infection [Abstract LB-6]. HEPATOLOGY 2010; 52(Suppl):107A.
  • 33
    Vierling JM, McHutchison JG, Jacobson IM, et al. GI-5005 therapeutic vaccine improves deficit in cellular immunity in IL28B genotype T/T, treatment-naive patients with chronic hepatitis C genotype 1 when added to standard of care (SOC) Peg-IFN-alfa-2A/ribavirin [Abstract 1973]. HEPATOLOGY 2010; 52(Suppl): 1258A.
  • 34
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
  • 35
    Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129; e18.
  • 36
    Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827; 7 e1.
  • 37
    Gane EJ, Stedman CA, Hyland RH, Sorensen RD, e al. Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with Gt2 or Gt3 [Abstract 34]. HEPATOLOGY 2011; 54(Suppl): 377A.
  • 38
    Gellad ZF, Naggie S, Reed SD, et al. The cost-effectiveness of a telaprevir-inclusive regimen as initial therapy for genotype 1 hepatitis C infection in individuals with the C/C IL28B polymorphism [Abstract 118]. HEPATOLOGY 2011; 54(Suppl): 417A.
  • 39
    Guedj J, Perelson AS. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. HEPATOLOGY 2011; 53: 1801-1808.
  • 40
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 41
    Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study [Abstract A13]. J Hepatol 2011; 54(Suppl): S6.
  • 42
    Fried M, Buti M, Dore GJ, Flisiak R, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIB study [Abstract LB-5]. HEPATOLOGY 2011; 54(Suppl): 1429A.
  • 43
    Sulkowski M, Asselah T, Ferenci P, et al. Treatment with the second generation HCV protease inhibitor BI201335 results in high and consistent SVR rates — results from SILEN-C1 in treatment naive patients across different baseline factors [Abstract 226]. HEPATOLOGY 2011; 54(Suppl): 473A.
  • 44
    Terrault N, Cooper C, Balart L, Larrey D, Box TD, et al. High sustained SVR 24 rates with response-guided danoprevir plus PEGIFNa2a and ribavirin in treatment-naive HCV genotype 1 patients: results from the ATLAS study [Abstract 79]. HEPATOLOGY 2011; 54(Suppl): 398A.
  • 45
    Lawitz E, Lalezari JP, Hassanein T, Kowdley K, et al. Once-daily PSI-7977 plus PEG/RBV in treatment-naive patients with HCV Gt1: robust end-of-treatment response rates are sustained post-treatment [Abstract 225]. HEPATOLOGY 2011; 54(Suppl): 472A.
  • 46
    Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin ion treatment-naive HCV-genotype 1 or 4 patients: phase 2B AI444010 study interim week 12 results [Abstract 227]. HEPATOLOGY 2011; 54(Suppl): 474A.